{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:26:03Z","timestamp":1792106763245,"version":"4.4.0"},"reference-count":86,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/14656566.2023.2297798","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:44:41Z","timestamp":1703166281000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Advances in non-biological drugs for the treatment of rheumatoid arthritis"],"prefix":"10.1080","volume":"25","author":[{"given":"Aliki I.","family":"Venetsanopoulou","sequence":"first","affiliation":[{"name":"Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.08.006"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05316-3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2022.2058178"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp165"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2020.10.006"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834540fb"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013562"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2106970"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Alivernini S Firestein GS McInnes IB The pathogenesis of rheumatoid arthritis. Immunity. 2022;55:2255\u20132270.","DOI":"10.1016\/j.immuni.2022.11.009"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4174"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.08.001"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424020-00004"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2022.61.04.04"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4555"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223358"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32805e87d0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2049238"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001158"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.179"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(10)80012-5"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0111-8"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19308"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171176"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh199"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.010298"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13184"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000958"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.7"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00009"},{"key":"e_1_3_4_41_1","first-page":"7","article-title":"La sulfasalazina: effetti collaterali e durata della terapia in pazienti affetti da artrite reumatoide [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis]","volume":"148","author":"Mundo A","year":"1997","unstructured":"Mundo A, Pedone V, Lamanna G, et al. La sulfasalazina: effetti collaterali e durata della terapia in pazienti affetti da artrite reumatoide [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis]. Clin Ter. 1997;148:7\u201313.","journal-title":"Clin Ter"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/86.8.501"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.3.222"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/30.6.413"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.1.104"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6544.420"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780361104"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331001"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.46.5.398"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92442-2"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90771-V"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205489"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.729"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.175"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092668"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23144"},{"key":"e_1_3_4_57_1","unstructured":"Hanoodi M Mittal M Methotrexate. [Updated 2023 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556114\/"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209212"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4328"},{"key":"e_1_3_4_60_1","unstructured":"Padda IS Goyal A Leflunomide. [Updated 2023 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557799\/"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.11.841"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)86732-6"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.798299"},{"key":"e_1_3_4_64_1","first-page":"1228","article-title":"Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial","volume":"116","author":"Bao C","year":"2003","unstructured":"Bao C, Chen S, Gu Y, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J (Engl). 2003;116:1228\u20131234.","journal-title":"Chin Med J (Engl)"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh500"},{"key":"e_1_3_4_66_1","first-page":"27","article-title":"Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide investigators\u2019 group","volume":"53","author":"Rozman B","year":"1998","unstructured":"Rozman B Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide investigators\u2019 group. J Rheumatol Suppl. 1998;53:27\u201332.","journal-title":"J Rheumatol Suppl"},{"key":"e_1_3_4_67_1","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri M","year":"2003","unstructured":"Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003;30:1182\u20131190.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<495:AID-ANR4>3.0.CO;2-U"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09403-3"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1984:AID-ART346>3.0.CO;2-B"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.07.020"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01300-7"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10083"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108027"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214618"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08513-4"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23449"},{"issue":"10","key":"e_1_3_4_79_1","article-title":"Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated [abstract]","volume":"68","author":"Register KA","year":"2016","unstructured":"Register KA, Cannella AC, Mikuls TR, et al. Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated [abstract]. Arthritis & Rheumat. 2016; 68 (suppl 10)","journal-title":"Arthritis & Rheumat"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6829358"},{"key":"e_1_3_4_81_1","first-page":"1521","article-title":"Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Kremer J","year":"2004","unstructured":"Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31:1521\u20131531.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05001-x"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081237"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00921-8"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60027-0"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303006"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34498"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1306381"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2297798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T08:01:18Z","timestamp":1707984078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2297798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/14656566.2023.2297798"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2297798","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}